The NHS and the pharmaceutical industry: High risk of harmful interactions.

Future healthcare journal Pub Date : 2025-06-30 eCollection Date: 2025-06-01 DOI:10.1016/j.fhj.2025.100257
Margaret McCartney
{"title":"The NHS and the pharmaceutical industry: High risk of harmful interactions.","authors":"Margaret McCartney","doi":"10.1016/j.fhj.2025.100257","DOIUrl":null,"url":null,"abstract":"<p><p>The pharmaceutical industry has been responsible for many interventions of great benefit to patients. However, great harm to patients and healthcare systems have been created through conflicts of interest, when the behaviours of individual doctors and healthcare systems have been compromised and patient harm has resulted. The interests of the pharmaceutical industry and the NHS cannot be assumed to overlap. This means that medical decision making should be as independent and unbiased as possible. Transparency about conflicts is important, but should be a means to the end it must be part of a system which stops conflicts harming patients and healthcare systems. Given the uncertainty of how the benefits of transparency can be used in practice, it is an imperative that conflicts are avoided, and not just 'managed'.</p>","PeriodicalId":73125,"journal":{"name":"Future healthcare journal","volume":"12 2","pages":"100257"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277477/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future healthcare journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.fhj.2025.100257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The pharmaceutical industry has been responsible for many interventions of great benefit to patients. However, great harm to patients and healthcare systems have been created through conflicts of interest, when the behaviours of individual doctors and healthcare systems have been compromised and patient harm has resulted. The interests of the pharmaceutical industry and the NHS cannot be assumed to overlap. This means that medical decision making should be as independent and unbiased as possible. Transparency about conflicts is important, but should be a means to the end it must be part of a system which stops conflicts harming patients and healthcare systems. Given the uncertainty of how the benefits of transparency can be used in practice, it is an imperative that conflicts are avoided, and not just 'managed'.

国民保健服务和制药业:有害相互作用的高风险。
制药业对许多对患者大有裨益的干预措施负有责任。然而,当个别医生和医疗保健系统的行为受到损害并对患者造成伤害时,利益冲突已经对患者和医疗保健系统造成了巨大伤害。不能假定制药业和NHS的利益重叠。这意味着医疗决策应尽可能独立和公正。关于冲突的透明度很重要,但它应该是达到目的的一种手段,它必须是阻止冲突伤害患者和卫生保健系统的系统的一部分。鉴于在实践中如何利用透明度的好处存在不确定性,避免冲突而不仅仅是“管理”冲突是当务之急。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信